A phase I/II study of rapamycin (sirolimus) in combination with methotrexate (MTX) and cyclosporine [ciclosporin] (CPS) in patients undergoing marrow transplantation from related donors mismatched for one HLA [human leukocyte antigen] antigen in the direction of graft-versus-host disease (GVHD).
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 21 Jun 2010
At a glance
- Drugs Sirolimus (Primary) ; Ciclosporin; Methotrexate
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 21 Jun 2010 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 19 Dec 2007 New trial record.